RA Capital, a multi-stage investment manager, led a $100m Series B funding round in Icosavax, a company that focused on developing safe and effective vaccines against infectious diseases. The round had participation from investors Janus Henderson, Perceptive Advisors, Viking Global, Cormorant Asset Management, Omega Funds, Surveyor Capital, Qiming Venture, Adams Street Partners, Sanofi Ventures and ND Capital. "There are currently no approved vaccines against RSV and hMPV, two respiratory viruses that are disproportionately life-threatening for the elderly. We are excited to lead this investment in Icosavax alongside a great syndicate to advance the combination RSV/hMPV candidate through development and into the clinic," Peter Kolchinsky, RA Capital Managing Partner.